The Protease ADAM17 at the Crossroads of Disease: Revisiting its Significance in Inflammation, Cancer, and Beyond
Files
(Published version)
Date
2024
Authors
Saad, M.I.
Jenkins, B.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
The FEBS Journal, 2024; 291(1):10-24
Statement of Responsibility
Mohamed I. Saad, and Brendan J. Jenkins
Conference Name
Abstract
The protease A Disintegrin And Metalloproteinase 17 (ADAM17) plays a central role in the pathophysiology of several diseases. ADAM17 is involved in the cleavage and shedding of at least 80 known membrane-tethered proteins, which subsequently modulate several intracellular signaling pathways, and therefore alter cell behavior. Dysregulated expression and/or activation of ADAM17 has been linked to a wide range of autoimmune and inflammatory diseases, cancer and cardiovascular disease. In this review, we provide an overview of the current state of knowledge from preclinical models and clinical data on the diverse pathophysiological roles of ADAM17, and discuss the mechanisms underlying ADAM17-mediated protein shedding and the potential therapeutic implications of targeting ADAM17 in these diseases.
School/Discipline
Dissertation Note
Provenance
Description
First published: 04 August 2023
Access Status
Rights
© 2023 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of 1 Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.